Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

249
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
249
Hepatitis01:25

Hepatitis

7
Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver.
7
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

329
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
329
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

466
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
466
Cystic Fibrosis: Management01:24

Cystic Fibrosis: Management

608
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
608
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

331
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
331

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-Centered Prescription Opioid Tapering Methods : A Randomized Clinical Trial.

Annals of internal medicine·2026
Same author

Different Experiences in Child and Family Team Meetings Between Child Welfare-Involved Families and Professionals.

Child maltreatment·2026
Same author

Are self-management skills associated with depressive symptoms, quality of life, and healthcare utilisation? A cross-sectional survey among patients with advanced cancer in the Netherlands.

BMJ open·2026
Same author

Patterns and Trends of Colorectal Cancer in the United Arab Emirates: A Retrospective Cohort Study, 2012-2021.

The Gulf journal of oncology·2026
Same author

Health systems science education for undergraduate medical students: a 3-year longitudinal curriculum preparing students to drive real-world health system improvement.

BMC medical education·2026
Same author

Validation of the extended version of the Implementation Leadership Scale (ILS-X).

Implementation science communications·2025

Related Experiment Video

Updated: Mar 20, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.4K

Cost-Effectiveness of the Hepatitis C Self-Management Program.

Erik J Groessl1,2, Marisa Sklar3, Diana D Laurent4

  • 11 VA San Diego Healthcare System, San Diego, CA, USA.

Health Education & Behavior : the Official Publication of the Society for Public Health Education
|May 22, 2016
PubMed
Summary

The Hepatitis C Virus (HCV) Self-Management Program improves quality of life and reduces costs. This low-cost intervention educates patients, enhancing outcomes from expensive antiviral treatments.

Keywords:
cost-effectivenesshealth care costshepatitis Cself-management

More Related Videos

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.4K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings
19:57

An Affordable HIV-1 Drug Resistance Monitoring Method for Resource Limited Settings

Published on: March 30, 2014

19.4K
Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model
23:56

Comprehensive & Cost Effective Laboratory Monitoring of HIV/AIDS: an African Role Model

Published on: October 31, 2010

17.4K
A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

24.8K

Area of Science:

  • Hepatology
  • Public Health
  • Health Economics

Background:

  • Many individuals with chronic Hepatitis C Virus (HCV) lack disease knowledge and are not optimal candidates for new antiviral medications.
  • Self-management interventions offer a pathway to educate patients, improve quality of life, and enhance treatment readiness.

Purpose of the Study:

  • To conduct a cost-effectiveness analysis of the HCV Self-Management Program.

Main Methods:

  • A randomized controlled trial (n=134) provided effectiveness data in Quality-Adjusted Life Years (QALYs).
  • Health care utilization and intervention costs were tracked from a payer's perspective.
  • Sensitivity analyses were performed to assess the robustness of the findings.

Main Results:

  • The HCV Self-Management Program resulted in cost savings of $586/person and a gain of 0.02975 QALYs after 1 year.
  • Intervention costs were $229/person, with participants experiencing $815/person lower health care costs.
  • An incremental cost-effectiveness ratio of $6,218/QALY was observed when excluding inpatient substance use treatment.

Conclusions:

  • The HCV Self-Management Program demonstrated improved QALYs and cost savings compared to information-only groups.
  • This low-cost intervention effectively educates HCV patients about treatment and transmission prevention.
  • Further research into low-cost interventions that augment expensive antiviral therapies is warranted.